Foundayo vs. Wegovy: GLP-1 oral duel

Lilly's oral Foundayo (orforglipron) saw 20,000+ patients begin dosing post-launch, 1,000 new scripts per day, 80% new-to-GLP1. Novo's Wegovy pill leads with tens of thousands on board in four months. Novo holds 2026 revenue/profit guidance at -5% to -13%.